The Biostatistics and Informatics shared resource (BISR), led by Matthew S. Mayo, PhD, MBA, FASA, is a critical and highly utilized shared resource that supports members of The University of Kansas Cancer Center. Mayo established this shared resource in 1998 and in 2002 was awarded a five-year $1.4 million NCI R24 shared resource grant for non-NCI designated centers to enhance the biostatistics and informatics infrastructure for the cancer center. The BISR has 5 aims: 1) Provide Statistical Expertise in Study Design for Cancer Center Projects, 2) Provide Informatics Capabilities to Support Data/Protocol Management, Monitoring and Training Complemented with new Tools for Hypothesis Generation and Cohort Identification, 3) Provide Monitoring Oversight and Perform Appropriate Analyses, 4) Participate in the Preparation of Study Presentations and Publications, and 5) Educate Cancer Center Researchers on Statistical Aspects of Cancer Research, that directly support the aims of cancer center and each program. Funding from the CCSG will enhance the BISR's ability to develop research grants and projects with cancer center members. From 2007 through 2010 the BISR has aided in the development of 129 grant applications of which 24% have been funded. The BISR also maintains an integrated research information system, which provides a centralized location for clinical protocol management within the same system that houses trial-specific data. This comprehensive system provides a web-accessible, single-source for obtaining the most up-to-date protocol information. Study-specific patient calendars can also be developed within this system to enhance protocol adherence. BISR staff also provides the education and training services for data entry personnel on cancer-related trials;hence, this integrated protocol and data management system enhances the quality control of Cancer Center clinical trials. In the coming year, we will augment the institutions clinical data repository, specifically to advance cancer research by allowing investigators to determine trial feasibility, characterize biospecimens and our cancer population by incorporating outcomes information from the tumor registry, and conduct survival analysis by incorporating the social security death index.
Biostatistics and Informatics are critical components to the success of basic, clinical and translational research. As such, the Biostatistics and Informatics Shared Resource works with investigators to ensure appropriate study design, analysis plans, and data management systems and informatics are in place to conduct and disseminate cancer research.
|Ledgerwood, Levi G; Kumar, Dhruv; Eterovic, Agda Karina et al. (2016) The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7:27185-98|
|Reed, Gregory A; Schiller, Gary J; Kambhampati, Suman et al. (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med 5:3031-3040|
|Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89|
|Parsel, S M; Grandis, J R; Thomas, S M (2016) Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 35:3217-26|
|(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675|
|Mitchell, Julie L; Seng, Amara; Yankee, Thomas M (2016) Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes. Immunology 149:400-412|
|Hamilton-Reeves, Jill M; Bechtel, Misty D; Hand, Lauren K et al. (2016) Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. Eur Urol 69:389-92|
|Kurahara, Hiroshi; Bohl, Christopher; Natsugoe, Shoji et al. (2016) Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Int J Cancer 139:628-38|
|Jiang, Yu; Guarino, Peter; Ma, Shuangge et al. (2016) Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application. Trials 17:336|
|(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401|
Showing the most recent 10 out of 93 publications